Q5134Inj, tyruko, 1 mg

Published CMS Medicare Part B payment-limit context for Q5134, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.

CMS payment limit

$24.494

per 1 MG · Medicare Part B

Up 0.7%from $24.321 in 2026-Q2

Current quarter: 2026-Q3FinalEffective July 1, 2026
Billing unit: 1 MG

Payment limit over time

$24.5182$24.2968

2024-Q4: Not published; 2025-Q1: Not published; 2025-Q2: Not published; 2025-Q3: Not published; 2025-Q4: Not published; 2026-Q1: Not published; 2026-Q2: $24.321; 2026-Q3: $24.494

No current FDA shortage matchThe latest completed FDA data has no affected record matching the Natalizumab ingredient family (FDA data as of August 20, 2026).

Email me when FDA shortage status changes

Tyruko

Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.

Other Natalizumab presentations

1 other CMS code

Source-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.

Swipe to see all columns

HCPCS	CMS description	Current quarter 2026-Q3	Prior quarter 2026-Q2	Change	NDCs	View history
J2323	Natalizumab injection	$24.406 per 1 MG	$24.321 per 1 MG	Up 0.3%

Email me when a new presentation appears

Put another code on your radar.

Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.

Explore CMS codes